CD79A and IgA glomerulonephritis: Although the effect of bevacizumab on the immune system is unclear, further analyses of bevacizumab and serum IgA are warranted, as bevacizumab reportedly affects the permeability of gastroduodenal and intestinal mucosa [17], which is known to produce mucosal IgA [18] and to be closely associated with IgA nephropathy development [19].